Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Accumulated Expenses for 3 consecutive years, with $25.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 14.59% to $25.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.5 million through Dec 2025, down 14.59% year-over-year, with the annual reading at $25.5 million for FY2025, 14.59% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $25.5 million at Inhibrx Biosciences, down from $27.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $43.3 million in Q4 2023, with the low at $23.9 million in Q2 2024.
  • Average Accumulated Expenses over 3 years is $30.1 million, with a median of $29.2 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses tumbled 30.96% in 2024, then rose 19.35% in 2025.
  • Over 3 years, Accumulated Expenses stood at $43.3 million in 2023, then crashed by 30.96% to $29.9 million in 2024, then fell by 14.59% to $25.5 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $25.5 million, $27.0 million, and $28.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.